CorMedix Inc. to Present at Multiple Investor and Industry Conferences

CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium), to Develop CRMD-005, a Proprietary Formulation of Taurolidine, for Rare Orphan Pediatric Tumors

CorMedix Inc. to Present at 2016 Rodman & Renshaw 18th Annual Global Investment Conference

CorMedix Inc. Invited to Present at Two Upcoming Scientific Conferences